BIIB076 Moves into Phase 1 for Alzheimer's Disease

BIIB076 has moved into phase 1 clinical testing to evaluate the safety, tolerability and pharmacokinetics of the RTM-derived anti-tau antibody in healthy volunteers and Alzheimer’s disease patients. BIIB076, a human recombinant monoclonal antibody targeting tau, was discovered by Neurimmune and acquired by Biogen in 2010. The clinical trial will be conducted by Biogen in the United States.